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Background: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). The aim
of this study was to explore the safety and efficacy of open-label tofacitinib following blinded treatment with
adalimumab or tofacitinib for moderate to severe RA.
Methods: Analyses included patients treated with adalimumab 40 mg once every 2 weeks or tofacitinib 10 mg
twice daily (BID) with background methotrexate (MTX) in a 12-month randomized study (NCT00853385), who
subsequently received tofacitinib 10 mg BID (with/without background MTX) in an open-label extension (NCT00413699).
Patients with treatment-related serious adverse events (AEs) and serious or recurrent infections in the index study
were excluded from the extension study. Exposure-adjusted incidence rates of safety-related events were assessed in
3-month and 12-month periods in the year before and in the year after switching. Efficacy was assessed 3 months
before, at the time of, and 3 months after switching.
Results: There were 233 (107 adalimumab to tofacitinib 10 mg BID, 126 blinded to open-label tofacitinib 10 mg BID)
patients included in these analyses. Patients in both treatment sequences had similar incidence rates (per
100 patient-years) of discontinuation due to AEs, serious AEs, and serious infections in the year before and in the year
after switching. Incidence rates of AEs were increased in the first 3 months after switching compared with the last
3 months before switching in both treatment groups. Switching from either blinded adalimumab or tofacitinib to
open-label tofacitinib resulted in numerically higher incidence of responders for signs and symptoms of disease and
improved physical function.
Conclusions: Treatment can be directly switched from adalimumab to tofacitinib. A similar safety and efficacy profile
was seen when patients received open-label tofacitinib after receiving either blinded adalimumab or tofacitinib.
Trial registration: ClinicalTrials.gov Identifiers: NCT00853385, registered 27 February 2009; NCT00413699, registered 18
December 2006.
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The long-term treatment of rheumatoid arthritis (RA)
often involves a sequence of different therapies. Patients
who have not responded to conventional synthetic
disease-modifying anti-rheumatic drugs (DMARDs) have
been routinely treated with a tumor necrosis factor
inhibitor (TNFi); however, approximately 20 % of
patients discontinue TNFi therapy within 12 months due
to inefficacy or adverse events (AEs) [1, 2]. Management
of patients who have not responded to treatment with
one TNFi may involve switching to another TNFi or
an agent with an alternative mechanism of action.
Several randomized controlled trials have demon-
strated the efficacy of agents with a different mechan-
ism of action versus placebo in patients with an
inadequate response to a TNFi [3–5]. In clinical prac-
tice, patients receiving a TNFi, such as adalimumab
(ADA), may need or choose to switch to an agent
with an alternative mechanism of action; an under-
standing of the impact of switching without an ex-
tended washout period is needed.
Tofacitinib is an oral Janus kinase inhibitor for the
treatment of RA [6]. The tofacitinib phase 3 program
included six randomized, controlled studies in which
tofacitinib was assessed in adult patients with active
moderate to severe RA [7–12] as monotherapy or
combined with conventional synthetic DMARDs. A
12-month, double-blind, randomized, controlled trial,
conducted in 115 centers worldwide, compared the
safety and efficacy of tofacitinib 5 or 10 mg twice
daily (BID) or ADA 40 mg every 2 weeks (Q2W) with
placebo in patients with active RA taking background
methotrexate (MTX; 7.5 to 25 mg weekly), who had
an inadequate response to MTX (defined as sufficient
residual disease activity to meet entry criteria). The
primary safety and efficacy data have been reported
previously [10]. Eligible patients who had participated
in this blinded study could be enrolled in an open-
label extension where they received tofacitinib 10 mg
BID (with or without background MTX), regardless of
their treatment in the blinded study [13].
The objective of the current analyses was to de-
scribe the safety and efficacy of open-label tofacitinib
in an extension study, following a direct switch from
blinded treatment with either ADA or tofacitinib for
the treatment of moderate to severe RA. The group
of patients who received blinded tofacitinib followed
by open-label tofacitinib in the extension study could
act as a control for such an assessment by represent-
ing potential changes to the clinical profile introduced
by transition from the double-blind to the open-label
study with minimal changes in treatment (dose ad-
justments permitted for concomitant RA medications
and tofacitinib in the extension study).Methods
Study design and treatment
ORAL Standard (A3921064; NCT00853385) was a
double-blind, phase 3 trial [10] in which patients were
randomly assigned to one of five regimens, all with
stable background MTX: tofacitinib 5 mg BID, tofaciti-
nib 10 mg BID, ADA 40 mg Q2W (subcutaneous
injection), placebo for 3 or 6 months followed by
tofacitinib 5 mg BID, and placebo for 3 or 6 months
followed by tofacitinib 10 mg BID for a total of 12 months.
ORAL Sequel (A3921024; NCT00413699) is an open-
label long-term extension study [13] in which all patients
from ORAL Standard were eligible to receive tofacitinib
10 mg BID with or without conventional synthetic
DMARDs. Exclusion criteria included treatment-related
serious AEs and serious or recurrent infections (includ-
ing serious or recurrent herpes zoster) in the index
study. Patients with latent tuberculosis were allowed to
continue in the extension study if they had received an
adequate course of therapy. Patients from certain coun-
tries (e.g., Korea, Croatia, Denmark, Czech Republic,
Germany, Spain, Sweden, Ireland and the United King-
dom) who enrolled in the extension study ≥14 days after
their final index study visit were excluded if their absolute
lymphocyte count (ALC) values were <750 cells/mm3.
Patients from the remaining countries were excluded if
their ALC values were <500 cells/mm3.
The current post-hoc analyses included patients who
were randomized at baseline to treatment with blinded
ADA 40 mg Q2W+MTX or blinded tofacitinib 10 mg
BID +MTX in ORAL Standard and subsequently received
open-label tofacitinib 10 mg BID (with or without MTX)
in the extension study. Although the patients initiated
treatment in the long-term extension with tofacitinib
10 mg BID, this could be reduced to 5 mg BID for safety
reasons. Additionally, dose adjustments, including tapering
and discontinuation (DC) of permitted concomitant RA
medications (such as MTX, prednisone and non-steroidal
anti-inflammatory drugs) were allowed in response to inad-
equate efficacy, disease improvement, or for safety reasons.
Each study was performed in compliance with the
Declaration of Helsinki and Good Clinical Practice
Guidelines established by the International Conference
on Harmonization. The final protocols, amendments,
and informed consent documentation were reviewed
and approved by the institutional review board and the
independent ethics committee of each investigational
center (Additional file 1: Table S1).
Patients
Patients in this analysis included those who were initially
enrolled in the phase 3, ORAL Standard study [10] and
subsequently elected to enroll in the extension study
[13]. Eligible patients in the phase 3 study were ≥18 years
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fied according to the American College of Rheumatology
(ACR) 1987 Revised Criteria [14] and had not failed or
had an AE to a TNFi in the past. Additional inclusion and
exclusion criteria have been described previously [10].
Patients who completed participation in the study or
discontinued for reasons other than treatment-related ser-
ious AEs and who met other inclusion/exclusion criteria
were invited to enroll in the long-term extension [13]. For
patients enrolling in the long-term extension study within
2 weeks of their last dose in the blinded study, baseline
values were obtained from the blinded study.
Statistical analyses
Post-hoc descriptive statistics are reported (data cutoff
date 19 April 2012). As the extension study is ongoing,Table 1 Baseline characteristics for patients randomized to double-b
mg twice daily (BID) in the phase 3 study [10] and for the subgroup
extension study [13]
Double-blind study
ADA 40 mg Tofa
n = 204 n =
Female, n (%) 162 (79.4) 168
White, n (%) 148 (72.5) 143
Age in years, mean ± SD 52.5 ± 11.7 52.9
Region of origin, %
North America 25.5 24.9
South America 2.9 1.5
Europe 53.9 55.7
Rest of world 17.6 17.9
Tender and swollen joints, mean
Tender 26.7 26.1
Swollen 16.4 15.8
Mean HAQ-DI score 1.5 1.5
Mean DAS28-4(ESR) 6.4 6.5
Mean CRP (mg/L) 17.5 17.3
Positive for rheumatoid factor, % 68.2 66.2
Positive for anti-CCP, % 74.8 64.0
Prior therapy, n (%)
TNF inhibitor 16 (7.8) 14 (
Non-TNF inhibitor biologic agent 3 (1.5) 4 (2
Disease-modifying drug other than MTX 114 (55.9) 115
Concomitant therapy, n (%)
Glucocorticoids 125 (61.3) 129
Lipid-lowering medication 10 (4.9) 10 (
aBaseline values at the start of the double-blind study; includes patients who comp
blinded study (or discontinued treatment for reasons other than a tofacitinib-relate
switched treatment with minimal washout (≤2 weeks after their last dose of study d
protein, DAS28-4(ESR) Disease Activity Score for 28-joint counts based on the erythr
Index, MTX methotrexate, RA rheumatoid arthritis, SD standard deviation, TNF tumothe study database has not yet been locked (i.e., some
values may change for the final, locked study database).
Safety and tolerability assessments
The incidence of treatment-emergent AEs (TEAEs) was
calculated at scheduled visits of the blinded study (baseline,
and months 1, 3, 6, 9, and 12) and extension study (base-
line, months 1, 2, 3, and every 3 months thereafter).
In the current analyses, the incidence of TEAEs was
compared during the last 3 months of blinded therapy
and the first 3 months of open-label treatment.
Exposure-adjusted incidence rates (and corresponding
95 % confidence intervals) of DCs due to AEs, serious
AEs and serious infections per 100 patient-years from
baseline were calculated for patients who completed
treatment with ADA 40 mg Q2W+MTX or tofacitiniblind adalimumab (ADA) 40 mg every 2 weeks or tofacitinib 10
who then received open-label tofacitinib 10 mg BID in the
Double-blind to open-label extensiona
citinib 10 mg ADA to tofacitinib Tofacitinib to tofacitinib
201 n = 107 n = 126
(83.6) 83 (77.6) 107 (84.9)
(71.1) 90 (84.1) 98 (77.8)












7.0) 12 (11.2) 10 (7.9)
.0) 1 (0.9) 3 (2.4)
(57.2) 66 (61.7) 80 (63.5)
(64.2) 63 (58.9) 77 (61.1)
5.0) 6 (5.6) 6 (4.8)
leted treatment with ADA 40 mg every 2 weeks or tofacitinib 10 mg BID in the
d serious adverse event (AE)) and then enrolled in the extension study and
rug in the blinded study). CCP cyclic citrullinated peptide, CRP C-reactive
ocyte sedimentation rate, HAQ-DI Health Assessment Questionnaire-Disability
r necrosis factor
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regardless of whether they entered the extension study,
and (2) who then enrolled in the extension study. These
analyses were performed for 3-month (months 0 − 3,
3 − 6, 6 − 9, and 9 − 12) and 12-month (months 0 − 12)
periods for both the blinded study and the first 12 months
of the extension study. Of note, there were two study visits
in the last 3 months of the blinded study (visits 5 and 6 at
months 9 and 12, respectively), and four study visits in the
first 3 months of the extension study (visits 1 − 4, for base-
line and months 1, 2, and 3).
Efficacy assessments
The following efficacy parameters were measured in pa-
tients who completed treatment with ADA +MTX orTable 2 Incidence of treatment-emergent adverse events (TEAEs), a









Number of patients (%)
DCs due to AEs 0 3 (2.8)
Serious AEs 1 (0.9) 8 (7.5)
Serious infections 0 2 (1.9)
Deaths 0 2 (1.9)a
Most commonly reported TEAEs
Number of patients (%)
Abdominal pain upper 0 1 (0.9)
Arthralgia 0 1 (0.9)
Bronchitis 4 (3.7) 3 (2.8)
Cough 0 1 (0.9)
Depression 0 1 (0.9)
Fall 1 (0.9) 1 (0.9)
Hemoglobin decreased 0 3 (2.8)
Headache 0 2 (1.9)
Nasopharyngitis 2 (1.9) 4 (3.7)
Nausea 1 (0.9) 3 (2.8)
Edema peripheral 1 (0.9) 0
Oropharyngeal pain 0 0
Upper respiratory tract infection 3 (2.8) 5 (4.7)
Urinary tract infection 0 5 (4.7)
Vomiting 0 2 (1.9)
Worsening RA 0 0
Includes patients who completed treatment with adalimumab (ADA) 40 mg every 2
treatment for reasons other than a tofacitinib-related serious adverse event (AE)) an
washout (≤2 weeks after their last dose of study drug in the blinded study). aOne p
study (it is unknown whether the patient took the study drug on this day). One pattofacitinib 10 mg +MTX in the blinded study (or dis-
continued for reasons other than a treatment-related
serious AE) and then switched to the tofacitinib 10 mg
group in the extension study: ACR response rates (20 %,
50 %, and 70 % improvement), mean change in Health
Assessment Questionnaire-Disability Index (HAQ-DI)
scores from the baseline of the blinded study, and
Disease Activity Score for 28-joint counts based on the
erythrocyte sedimentation rate (DAS28-4(ESR)) <2.6 re-
sponse rates at: (1) month 9 (visit 5) of the blinded study
(“-3 months” relative to the switch); (2) the time of
switching from the blinded to the extension study
(“switch”), and (3) month 3 (visit 4) of the extensions
study (“+3 months”) allowing visit windows of ±1.5 months
to capture all efficacy and safety data.nd the most commonly reported TEAEs (occurring in ≥2 % of





−3 months to switch
(tofacitinib)
Switch to +3 months
(tofacitinib)
1 (0.8) 3 (2.4)
4 (3.2) 8 (6.3)
1 (0.8) 2 (1.6)
0 0
4 (3.2) 1 (0.8)
4 (3.2) 2 (1.6)
6 (4.8) 2 (1.6)
1 (0.8) 3 (2.4)
3 (2.4) 1 (0.8)
3 (2.4) 1 (0.8)
0 1 (0.8)
0 2 (1.6)
5 (4.0) 3 (2.4)
1 (0.8) 1 (0.8)
2 (1.6) 3 (2.4)
0 3 (2.4)
3 (2.4) 6 (4.8)
2 (1.6) 0
1 (0.8) 0
3 (2.4) 2 (1.6)
weeks or tofacitinib 10 mg twice daily in the blinded study (or discontinued
d then enrolled in the extension study and switched treatment with minimal
atient committed suicide 1 day after the first tofacitinib dose in the extension
ient died due to lung malignancy. DC discontinuation, RA rheumatoid arthritis
Table 3 Adverse events and change from baseline in selected laboratory variables during the phase 3 double-blind study [10] and the open-label extension study [13]
Double-blind studya Open-label extension studyb
IR per 100 patient-years
(95 % CI)
0 − 3 months 3 − 6 months 6 − 9 months 9 − 12 months Total 12 months 0 − 3 months 3 − 6 months 6 − 9 months 9 − 12 months Total
12 months
ADA 40 mg Q2W (blinded study) to tofacitinib 10 mg BID (extension study)
ADA 40 mg Q2W Tofacitinib 10 mg BID
N = 204 N = 187 N = 177 N = 163 N = 204 N = 145 N = 130 N = 124 N = 121 N = 145
DCs due to AEs 16.3 (9.0, 29.5) 19.2 (9.6, 38.4) 6.7 (2.1, 20.7) 4.1 (0.6, 29.3) 12.9 (8.6, 19.4) 10.0 (4.2, 24.0) 9.6 (3.1, 29.9) 3.3 (0.5, 23.6) 12.0 (3.9, 37.2) 8.8 (5.0, 15.6)
Serious AEs 8.9 (4.0, 19.9) 16.8 (8.0, 35.2) 6.7 (2.2, 20.7) 8.2 (2.1, 32.9) 10.3 (6.5, 16.3) 16.1 (8.0, 32.2) 16.2 (6.8, 39.0) 6.7 (1.7, 26.7) 8.0 (2.0, 31.8) 13.0 (8.1, 20.9)
Serious infections 0 4.8 (1.2, 19.1) 2.2 (0.3, 15.8) 0 1.7 (0.5, 5.2) 4.0 (1.0, 15.9) 0 3.3 (0.5, 23.7) 4.0 (0.6, 28.1) 2.9 (1.1, 7.9)
Tofacitinib 10 mg BID (blinded study) to tofacitinib 10 mg BID (extension study)
Tofacitinib 10 mg BID Tofacitinib 10 mg BID
N = 201 N = 184 N = 173 N = 157 N = 201 N = 146 N = 128 N = 122 N = 109 N = 146
DCs due to AEs 16.7 (9.3, 30.2) 22.2 (11.6, 42.7) 6.8 (2.2, 21.1) 0.0 (0.0, 0.0) 13.3 (8.8, 20.0) 13.9 (6.6, 29.1) 3.3 (0.5, 23.2) 10.5 (3.4, 32.5) 4.4 (0.6, 31.5) 9.1 (5.2, 16.0)
Serious AEs 20.1 (11.6, 34.5) 12.3 (5.1, 29.6) 9.1 (3.4, 24.2) 8.7 (2.2, 34.8) 13.7 (9.1, 20.6) 18.0 (9.4, 34.6) 9.9 (3.2, 30.6) 14.0 (5.3, 37.3) 4.4 (0.6, 31.5) 13.4 (8.3, 21.5)
Serious infections 4.6 (1.5, 14.2) 2.4 (0.3, 17.3) 4.5 (1.1, 18.1) 4.3 (0.6, 30.7) 4.0 (1.9, 8.4) 5.9 (1.9, 18.4) 3.3 (0.5, 23.2) 3.5 (0.5, 24.8) 4.4 (0.6, 31.5) 4.5 (2.0, 10.1)
Double-blind studyb Long-term extension studyb
Mean change from
baseline (SD)
Month 1 Month 3 Month 6 Month 9 Month 12 Month 1 Month 3 Month 6 Month 9 Month 12
ADA 40 mg Q2W (blinded study) to tofacitinib 10 mg BID (extension study)
ADA 40 mg Q2W Tofacitinib 10 mg BID
N = 142 N = 142 N = 141 N = 138 N = 132 N = 132 N = 126 N = 118 N = 118 N = 110
Absolute lymphocyte count,
cells/mm3
0.4 (0.6) 0.4 (0.6) 0.4 (0.6) 0.4 (0.6) 0.4 (0.7) 0.5 (0.8) 0.2 (0.6) 0.0 (0.6) -0.0 (0.6) -0.0 (0.6)
N = 142 N = 144 N = 144 N = 140 N = 137 N = 139 N = 131 N = 125 N = 122 N = 115
Total cholesterol, mg/dL 8.3 (26.4) 6.7 (30.1) 2.8 (29.4) -0.1 (29.7) 3.2 (33.9) 22.8 (33.2) 24.5 (38.2) 18.9 (36.4) 20.8 (35.6) 18.8 (37.7)
N = 140 N = 141 N = 142 N = 139 N = 134 N = 1 N = 3 N = 121 N = 2 N = 107
LDL, mg/dL 3.2 (20.5) 2.5 (24.9) 0.5 (24.3) -3.5 (23.1) -1.8 (27.0) 18.9 (N/A) -6.2 (57.8) 6.2 (30.2) 36.0 (25.5) 8.6 (31.9)
N = 142 N = 144 N = 143 N = 140 N = 135 N = 1 N = 3 N = 122 N = 2 N = 108
HDL, mg/dL 3.3 (9.2) 3.4 (10.0) 1.6 (11.3) 3.3 (11.5) 5.6 (10.5) 20.9 (N/A) 13.1 (24.5) 11.9 (11.8) 10.5 (30.4) 8.8 (12.3)
N = 142 N = 144 N = 143 N = 140 N = 135 N = 1 N = 5 N = 122 N = 3 N = 108














Table 3 Adverse events and change from baseline in selected laboratory variables during the phase 3 double-blind study [10] and the open-label extension study [13]
(Continued)
Tofacitinib 10 mg BID (blinded study) to tofacitinib 10 mg BID (extension study)
Tofacitinib 10 mg BID Tofacitinib 10 mg BID
N = 142 N = 141 N = 141 N = 138 N = 129 N = 134 N = 131 N = 116 N = 112 N = 103
Absolute lymphocyte count,
cells/mm3
0.2 (0.5) -0.0 (0.5) -0.1 (0.6) -0.1 (0.6) -0.3(0.6) -0.1 (0.6) -0.2 (0.6) -0.3 (0.6) -0.3 (0.6) -0.3 (0.6)
N = 145 N = 142 N = 141 N = 136 N = 131 N = 136 N = 134 N = 122 N = 117 N = 106
Total cholesterol, mg/dL 28.7 (29.2) 27.4 (31.7) 30.0 (34.3) 29.3 (36.6) 32.8 (37.2) 30.6 (33.9) 27.6 (38.8) 22.5 (42.2) 23.7 (36.3) 29.7 (32.7)
N = 141 N = 139 N = 137 N = 133 N = 123 N = 0 N = 5 N = 117 N = 4 N = 100
LDL, mg/dL 18.7 (25.6) 19.1 (25.5) 20.7 (31.0) 19.8 (31.1) 20.0 (31.8) N/A 9.8(28.4) 13.1 (35.8) 16.3(42.5) 20.7 (30.7)
N = 145 N = 142 N = 141 N = 136 N = 127 N = 0 N = 5 N = 121 N = 4 N = 103
HDL, mg/dL 8.0 (12.4) 6.1 (14.1) 7.7 (17.9) 7.1 (15.4) 8.2 (15.7) N/A 16.1 (19.0) 8.6 (19.1) 7.9 (3.9) 9.0 (15.2)
N = 145 N = 142 N = 141 N = 136 N = 127 N = 0 N = 7 N = 121 N = 4 N = 103
Triglycerides, mg/dL 9.2 (65.0) 8.4 (69.4) 13.0 (87.3) 12.3 (91.0) 15.0 (83.3) N/A 25.5 (69.2) 12.9 (84.8) 6.6 (61.7) 7.5 (70.1)
aIncludes patients who were treated with adalimumab (ADA) 40 mg every 2 weeks (Q2W) or tofacitinib 10 mg twice daily (BID) from baseline in the blinded study, regardless of whether they entered the extension
study. bIncludes all patients who completed treatment with ADA 40 mg Q2W or tofacitinib 10 mg BID in the blinded study and then switched treatment and completed 12 months of the extension study. Please see
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Patient disposition and demographics
Of 204 patients randomized to ADA 40 mg Q2W+MTX
in the blinded study, 107 switched to open-label tofacitinib
10 mg BID (105 (98 %) with MTX on day 1) within
2 weeks after their last dose of ADA. Of 201 patients ran-
domized to blinded tofacitinib 10 mg BID +MTX in the
blinded study, 126 switched to open-label tofacitinib
10 mg BID (123 (98 %) with MTX on day 1) within
2 weeks. Patient demographic and baseline characteristics
were similar across sequences and between those patients
who were randomized to ADA 40 mg Q2W+MTX or
tofacitinib 10 mg BID +MTX in the blinded study and
those who then received tofacitinib 10 mg BID (with or
without MTX) in the extension study (Table 1).
Safety and tolerability
On analysis of the proportions of patients with TEAEs
occurring 3 months prior to and 3 months after the
switch, there was no clear pattern of changes in either
the ADA to tofacitinib group or the blinded to open-
label tofacitinib group (Table 2). Incidence rates per 100
patient-years of DCs due to AEs, serious AEs, andTable 4 Patient-level serious adverse events from switch to +3 mon
Serious AE Days after
in the exte
ADA 40 mg Q2W (blinded study) to tofacitinib 10 mg BID (extension study),
Suicide (n = 1) 1a
Osteonecrosis (n = 1) 23
Post-operative abscess (n = 1) 44
Infectious peritonitis/appendicitis/intervertebral disc
disorder (n = 1 each; same patient)
44/46/51
Autoimmune hepatitis (possible drug-induced liver injury; n = 1) 55
Fractured ischium (n = 1) 109
Spondylolisthesis/stenosis/lung malignancy (n = 1 each;
same patient)
117/117/13
Fractured femur (n = 1) 134
Tofacitinib 10 mg BID (blinded study) to tofacitinib 10 mg BID (extension stu
Sinusitis (n = 1) 13
Dyspnea/tendon rupture (n = 1 each; same patient) 37/53
Cervical dysplasia (n = 1) 52
Malignant melanoma (n = 1) 85
Vertigo (n = 1) 89
Disseminated herpes simplex (n = 1) 94
Cervical vertebral fracture/fall (n = 1 each; same patient) 102/102
Lung infiltration/atrial fibrillation (n = 1 each; same patient)c 107/122
Goiter (n = 1) 120
Includes patients who completed treatment with adalimumab (ADA) 40 mg every 2 wee
treatment for reasons other than a tofacitinib-related serious adverse event (AE)) and t
washout (≤2 weeks after their last dose of study drug in the blinded study). aUnknown
fibrillation (day 122) occurred after drug discontinuation (day 107)serious infections over 3-month and 12-month periods
were similar in the year before and in the year after
switching in both groups (Table 3). Incidence rates were
increased in the first 3 months of the extension study
(0 − 3 months) compared with the last 3 months of
the blinded study (9 − 12 months) for both groups.
In the extension study, small increases from baseline in
ALC were observed at month 1 and month 3 in patients in
the ADA to tofacitinib group; ALC levels returned to base-
line at month 6 and were maintained through month 12.
Small decreases from baseline in ALC were observed at all
time points through month 12 in patients in the blinded to
open-label tofacitinib group (Table 3). In the extension
study, patients in the ADA to tofacitinib group and patients
in the blinded to open-label tofacitinib group had small
increases from baseline in total cholesterol, low-density
lipoprotein (LDL), high-density lipoprotein (HDL) and tri-
glycerides at all time points through month 12 (except for
LDL at month 3 in patients in the ADA to tofacitinib
group) (Table 3). At month 3 of the extension study, 2 pa-
tients (2 %) in the ADA to tofacitinib group and 4
patients (3 %) in the blinded to open-label tofacitinib













2 Not applicable Deathb
Temporarily withdrawn Recovered





Dose not changed Not recovered
Permanently withdrawn Recovered
Dose not changed Recovering
Permanently withdrawn Recovered/not applicable
Temporarily withdrawn Recovered
ks (Q2W) or tofacitinib 10 mg twice daily (BID) in the blinded study (or discontinued
hen enrolled in the extension study and switched treatment with minimal
whether the patient took study drug on this day. bDue to lung malignancy. cAtrial
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tension study - that is, following the switch to tofacitinib -
are presented in Table 4 alongside the action taken and
patient outcomes. Two serious AEs resulted in death (lung
malignancy, n = 1 (day 132); suicide, n = 1 (day 1); it is
unknown whether the patient took the study drug on
this day). One patient who developed vertigo during
this period was still experiencing it 20 months later. All
other patients who experienced a serious AE in the
first 3 months of the extensions study recovered from
the AE.
Efficacy
Greater proportions of patients had improvement in the
signs and symptoms of RA, as measured by increased
ACR response rates (Fig. 1) and reductions in mean
DAS28-4(ESR), during the first 3 months of the extension
study compared with the last 3 months of the blinded
study in both the ADA to tofacitinib group and the
blinded to open-label tofacitinib group (Fig. 2a). Of the 74
patients on ADA and 84 patients on tofacitinib who
achieved an ACR20 response 3 months prior to
switching in the double-blind study, 7 % (n = 5) and
7 % (n = 6), respectively, did not maintain an ACR20
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Fig. 1 American College of Rheumatology (ACR) response rates 3 months b
BID twice daily. *Includes patients who completed treatment with ADA 40
treatment for reasons other than a tofacitinib-related serious AE) and then
washout (≤2 weeks after their last dose of study drug in ORAL Standard). A
reduction in the number of tender and swollen joints, as well as 20/50/70%
adalimumab; BID, twice daily; Q2W, every 2 weeksSimilarly, further improvement in physical function, as
measured by greater mean reductions in HAQ-DI score
from baseline, was seen in both treatment groups (Fig. 2b).
Discussion
The clinical, functional, and radiographic efficacy and safety
of tofacitinib 5 and 10 mg BID with and without MTX has
been reported in patients with active RA in randomized
phase 2 [15–19] and phase 3 studies [7–12]. The phase 3
study that included an ADA treatment arm demonstrated
efficacy and safety results of tofacitinib consistent with the
other phase 3 studies [10]. The current analyses describe
the safety and efficacy of open-label tofacitinib (with or
without MTX) following a direct switch from blinded
treatment with either ADA+MTX or tofacitinib +MTX.
Both proportions and exposure-adjusted incidence rates
of DCs due to AEs, serious AEs, and serious infections
over time were similar when switching from blinded ADA
or tofacitinib to open-label tofacitinib. The increased inci-
dence rates for these events in the initial 3 months of
open-label tofacitinib, compared with the last 3 months of
either blinded ADA or tofacitinib, suggests that these dif-
ferences may be due to aspects of the study design inher-
ent in the transition period rather than as a result of any
overlapping immunomodulatory effects of ADA and tofa-
citinib. One potential explanation for the observedOpen-label
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b)
Double-blind Switch Open-label
ADA 40 mg Q2W (n = 106)
Tofacitinib 10 mg BID (n = 125)





ADA 40 mg Q2W to tofacitinib 10 mg BID (n = 99)
Tofacitinib 10 mg BID to tofacitinib 10 mg BID  (n = 122)
Fig. 2 Disease Activity Score for 28-joint counts based on the erythrocyte sedimentation rate (DAS28-4(ESR)) and changes from baseline in the
Health Assessment Questionnaire-Disability Index (HAQ-DI) 3 months before switch, at switch, and 3 months after switch*. ADA adalimumab,
BID twice daily. *Includes patients who completed treatment with ADA 40 mg Q2W or tofacitinib 10 mg BID in ORAL Standard (or discontinued
treatment for reasons other than a tofacitinib-related serious AE) and then enrolled in ORAL Sequel and switched treatment with minimal washout
(≤2 weeks after their last dose of study drug in ORAL Standard). Lower scores indicate less disease activity (DAS28–4[ESR]) or lower disability (HAQ-DI).
ADA, adalimumab; BID, twice daily; DAS28–4(ESR), Disease Activity Score for 28 joint counts based on the erythrocyte sedimentation rate; HAQ-DI,
Health Assessment Questionnaire-Disability Index; Q2W, every 2 weeks; SE, standard error. (a) Changes from Baseline in Disease Activity Score for 28-
joint counts based on Erythrocyte sedimentation rate (DAS28-4(ESR) 3 months before switch, at switch, and 3 months after switch.* (b) Changes from
Baseline in the Health Assessment QUestionnaire-Disability Index (HAQ-DI) 3 months before switch, at switch, and 3 months after switch*
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fect. For example, the transition from the double-blind
study to the open-label extension study may have driven
an increase in patient/investigator sensitivity to reporting,
whereby there was increased attribution of events in the
extension study. Another limitation could have been thenumber of visits per 3-month period. Patients in the ex-
tension study had more frequent visits over the first
3 months of treatment (four visits) than they had in the
final 3 months of the blinded study (two visits); thus, there
were more opportunities to report an event in the first
3 months after the switch, which could have had an
Genovese et al. Arthritis Research & Therapy  (2016) 18:145 Page 10 of 11impact on the apparent incidence rate. Although a mech-
anistic or immunologic origin for the difference in safety
profile cannot be ruled out, it is thought to be unlikely, as
an increase was observed in both treatment sequences.
On analysis of the proportions of patients experiencing
TEAEs for 3 months before and 3 months after the switch,
there was no clear pattern of changes during the switch. A
further limitation is the potential change in dosing of per-
mitted concomitant RA medications, including MTX,
after switching.
Although the analyses of incidence rates per 100
patient-years of AEs in the blinded study included all pa-
tients regardless of whether they entered the extension,
the data for the extension study included only those
patients who completed the blinded study (that is, those
who had data for the last 3 months of this study and
who then enrolled in the extension). This introduces a
potential censoring/truncation effect that is associated
with identifying and analyzing a “completer” population.
This effect may also apply to the efficacy response: pa-
tients with lesser efficacy responses may have been less
likely to remain in the extension study to month 3,
thereby, leading to seemingly greater improvements at
month 3 among patients in this study. However, the
incidence of both DCs and improvements in efficacy
during the first 3 months of the extension study were
similar between those patients who switched to ADA
and those who continued to receive tofacitinib.
With these limitations in mind, we observed that
switching directly from double-blind ADA 40 mg Q2W
to open-label tofacitinib 10 mg BID resulted in sustained
clinical response, with numeric improvements in all
ACR response rates assessed, DAS28-4(ESR) scores, and
mean change from baseline in HAQ-DI scores. Efficacy
assessed at the same time points was similar in the
double-blind tofacitinib 10 mg BID to open-label tofaci-
tinib 10 mg BID group and the ADA to tofacitinib
10 mg BID group, and there was a similar pattern of in-
creases in efficacy from the double-blind to the open-
label extension.
One of the questions of interest was whether there are
clinical consequences of potential overlapping immuno-
modulatory effects in the switch from ADA to tofaciti-
nib. Analysis of AEs do not support such a conclusion
but, in contrast, the contribution that overlapping
pharmacologic exposure to ADA and tofacitinib makes
to efficacy may be more difficult to assess. Although the
first efficacy assessment at 3 months is well beyond the
terminal half-life of the last dose of ADA [20, 21],
pharmacodynamic effects may persist beyond what
might be predicted from half-life/clearance data, and co-
administered MTX reduces ADA clearance [22]. Never-
theless, efficacy assessed at the same time points was
similar in the tofacitinib to tofacitinib group and theADA to tofacitinib group, with similar numeric patterns
of improvement.
Conclusions
In summary, analysis of incidence rates of AEs showed a
similar pattern over time for both ADA to tofacitinib
and blinded to open-label tofacitinib treatment se-
quences in the year before and the year after switching,
and there was no clear pattern of changes in TEAEs in
the 3 months before and 3 months after the switch.
Switching from both double-blind ADA and tofacitinib
to open-label tofacitinib resulted in numeric improve-
ments in signs and symptoms of disease and physical
function. These results indicate that a patient’s treatment
can be directly switched from ADA to tofacitinib 10 mg
BID, with a safety and efficacy profile similar to switch-
ing from blinded to open-label tofacitinib 10 mg BID.
This analysis did not address potential differences be-
tween the safety profiles of ADA and tofacitinib in the
phase 3 study for this cohort of patients, as this com-
parison is more appropriate in the primary safety ana-
lysis population [10].
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